We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
BioXcel Therapeutics is a clinical stage biopharmaceutical company focused on drug development in neuroscience and immuno-oncology utilizing artificial intelligence. Currently the company has two lead clinical development programs:
o BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders
• Reported positive results from Phase 1b trial of intravenously-dosed Dexmedetomidine supporting BXCL501 development in schizophrenia
• Data from Phase 1b PK/PD safety study in mild probable Alzheimer’s patients expected in second half of 2018
o BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer
• Announced FDA acceptance of IND for treatment emergent neuroendocrine prostate cancer; study expected to be initiated in fourth quarter of 2018
• Entered clinical partnership with Nektar for study in pancreatic cancer